Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Pelthos Therapeutics (NYSE American: PTHS), a biopharmaceutical company, announced its participation in the upcoming Wells Fargo Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS), a biopharmaceutical company, announced its participation in the upcoming Wells Fargo Healthcare Conference. CEO Scott Plesha and CFO Frank Knuettel will deliver a presentation on Wednesday, September 3rd, 2025 at 1:30 p.m. ET.
The presentation will be accessible via webcast on the Events and Presentations section of Pelthos' website, with replays available for 90 days following the event. Institutional investors interested in one-on-one meetings should contact their sales representatives.
Details
News Market Reaction – PTHS
On Sep 2, the day this news came out, PTHS closed 5.03% below the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 pm (ET)
DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 p.m. E.T.
For one-on-one meeting requests please contact your institutional sales representative. A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website at https://pelthos.com. Archived replays will be available for 90 days following the event.
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel,
Contacts
Pelthos Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.